Advertisement
CRON vs TLRY
Which Stock Would AI Choose? Cronos Group (CRON) vs. Tilray Brands (TLRY) Stock Comparison
Key Takeaways
- CRON is delivering record revenue, gross profit, and adjusted EBITDA, while TLRY remains profitable only on an adjusted basis and continues to report GAAP (generally accepted accounting principles) net losses.
- CRON carries roughly $841 million in cash and investments with essentially no dilution pressure, whereas TLRY has leaned on debt-for-equity swaps, ATM (at-the-market) equity issuance, and a reverse stock split.
- Tickeron AI Verdict: Based on trend consistency, balance-sheet strength, and relative momentum, the AI currently favors CRON over TLRY.
- For more context, explore CRON Major News and CRON Today's Price Move, as well as TLRY Major News and TLRY Today's Price Move.
- To see how AI trading systems are positioning across the market, visit the Trending AI Robots page.
Introduction
Two of the most closely followed names in the global cannabis sector, Cronos Group and Tilray Brands, have followed sharply different paths in recent quarters. This stock comparison is relevant for investors weighing a focused, cash-rich Canadian operator against a diversified consumer packaged-goods platform spanning cannabis, beverages, and pharmaceutical distribution. Both companies compete in Canada and Europe, yet their financial profiles and market positioning diverge meaningfully. Growth-oriented traders and longer-horizon investors alike may find this contrast instructive when assessing relative performance, profitability, and risk in an industry still shaped by regulatory change and intense price competition.
CRON Overview and Recent Performance
CRON, or Cronos Group Inc., is a Canadian cannabinoid company focused on branded cannabis products across Canada, Israel, and emerging European markets. In recent weeks, the company reported record third-quarter net revenue of roughly $63.5 million, up about 75% year over year, alongside record gross profit and record adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). Operating income turned positive, and gross margin reached approximately 51%.
The company's Spinach and SOURZ brands continue to gain Canadian market share, while its PEACE NATURALS brand has now delivered eleven consecutive record quarters in Israel. International revenue outside Israel expanded roughly sevenfold, led by Germany. Recent market activity has also been shaped by the October completion of Cronos's acquisition of CanAdelaar, described as Europe's largest adult-use cannabis company, which gives it a foothold in the Dutch adult-use pilot program. A balance sheet holding about $841 million in cash and investments, combined with ongoing share repurchases, has supported sentiment and stability.
TLRY Overview and Recent Performance
TLRY, or Tilray Brands Inc., operates a more diversified model: cannabis accounts for a minority of sales, with the balance spread across craft beverages, wellness products, and pharmaceutical distribution. For its recently completed fiscal year, Tilray reported revenue of roughly $915 million, up about 11%, and adjusted EBITDA near $61 million. International cannabis revenue grew more than 30%, driven by Germany, the United Kingdom, and other European markets.
However, on a GAAP basis, the company continued to post net losses, and it has relied on dilutive financing, including debt-for-equity swaps and at-the-market equity issuance, to strengthen its balance sheet. A 1-for-10 reverse stock split took effect in late 2025 to support its Nasdaq listing. Recent weeks have also brought a "Reduce" rating from a sell-side analyst and a share price that has remained well below earlier highs, reflecting persistent concerns over dilution and beverage-segment softness even as management advances cost-savings programs and a partnership with Carlsberg.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots drawn from a much larger universe of automated strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance record, and set of tickers, ranging from swing-trading systems to longer-horizon trend followers. Traders can review statistics such as win rates, trade counts, and historical results to identify approaches that align with their objectives. Exploring the Trending AI Robots page can help investors see how automated systems are currently reading momentum across the market.
Head-to-Head Comparison
The clearest contrast between the two companies is focus versus diversification. CRON is a pure-play cannabis operator with a lean cost structure, positive operating income, and a fortress-like balance sheet that allows share buybacks rather than dilution. Its growth is concentrated in Canada, Israel, and select European markets, giving it a cleaner but narrower catalyst set.
TLRY, by contrast, is a multi-segment consumer platform with a substantially larger revenue base and greater geographic breadth. That diversification reduces reliance on any single cannabis market but also dilutes exposure to regulatory catalysts and introduces beverage and distribution risks. Tilray's adjusted profitability is improving, yet GAAP losses, share dilution, and a recent reverse split weigh on market sentiment. On momentum, Cronos has shown more consistent operational execution and stronger relative stock performance, while Tilray continues to work through balance-sheet and margin challenges.
Tickeron AI Verdict
Weighing observable factors such as trend consistency, balance-sheet stability, profitability trajectory, and relative positioning, Tickeron's AI would likely favor CRON over TLRY in the current environment. Cronos's record revenue and adjusted EBITDA, positive operating income, substantial cash reserves, and lack of dilution pressure suggest a more durable trend profile, while Tilray's persistent GAAP losses and financing headwinds introduce greater uncertainty. This assessment is probabilistic rather than definitive, and market conditions can shift quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRON is a Buy and TLRY is a Buy.
CRON in upward trend: price rose above 50-day moving average on November 02, 2026
CRON moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 62 of 71 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CRON as a result. In 80 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for CRON just turned positive on October 21, 2026. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in 45 of 58 cases over the following month. The odds of a continued upward trend are 78%.
The 10-day moving average for CRON crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +10.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in 170 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 97 of 131 cases where CRON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for CRON moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 55 cases where CRON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
CRON broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.245) is normal, around the industry mean (6.379). P/E Ratio (19.000) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (6.993) is also within normal values, averaging (183.387).
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
TLRY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TLRY turned positive on November 04, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Oscillator exited the oversold zone, 38 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 46 cases where TLRY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLRY as a result. In 74 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLRY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (6.379). P/E Ratio (-2.679) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
CRON | TLRY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 80 | 93 | |
PRICE GROWTH RATING 1..100 | 41 | 88 | |
P/E GROWTH RATING 1..100 | 68 | 14 | |
SEASONALITY SCORE 1..100 | 17 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TLRY's Valuation (22) in the Biotechnology industry is in the same range as CRON (52) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to CRON’s over the last 12 months.
TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to CRON’s over the last 12 months.
CRON's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as TLRY (93) in the Biotechnology industry. This means that CRON’s stock grew similarly to TLRY’s over the last 12 months.
CRON's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for TLRY (88) in the Biotechnology industry. This means that CRON’s stock grew somewhat faster than TLRY’s over the last 12 months.
TLRY's P/E Growth Rating (14) in the Biotechnology industry is somewhat better than the same rating for CRON (68) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew somewhat faster than CRON’s over the last 12 months.
| CRON | TLRY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 89% |
| Advances ODDS (%) | 8 days ago 73% | 9 days ago 79% |
| Declines ODDS (%) | 3 days ago 75% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 89% | N/A |
| Aroon ODDS (%) | 2 days ago 74% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRON’s FA Score shows that 0 FA rating(s) are green while TLRY’s FA Score has 2 green FA rating(s).
- CRON’s FA Score: 0 green, 5 red.
- TLRY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRON’s TA Score shows that 6 TA indicator(s) are bullish while TLRY’s TA Score has 3 bullish TA indicator(s).
- CRON’s TA Score: 6 bullish, 4 bearish.
- TLRY’s TA Score: 3 bullish, 4 bearish.
Price Growth
CRON (@Pharmaceuticals: Generic) experienced а -1.71% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was -11.82% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.13%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was +10.54%.
Reported Earning Dates
CRON is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.13% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
CRON and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To CRON | 1D Price Change % | ||
|---|---|---|---|---|
| CRON | 100% | +1.17% | ||
| SNDL - CRON | 73% Closely correlated | +2.16% | ||
| ACB - CRON | 59% Loosely correlated | -1.17% | ||
| CGC - CRON | 58% Loosely correlated | +2.13% | ||
| TLRY - CRON | 57% Loosely correlated | -1.51% | ||
| TRLV - CRON | 55% Loosely correlated | +1.26% | ||
More | ||||
TLRY and
Correlation & Price change
A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To TLRY | 1D Price Change % | ||
|---|---|---|---|---|
| TLRY | 100% | -1.51% | ||
| SNDL - TLRY | 76% Closely correlated | +2.16% | ||
| CGC - TLRY | 75% Closely correlated | +2.13% | ||
| ACB - TLRY | 65% Loosely correlated | -1.17% | ||
| CRON - TLRY | 64% Loosely correlated | +1.17% | ||
| GLAS - TLRY | 59% Loosely correlated | -5.08% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| WAVES.X | 0.185018 | 0.003024 | +1.66% |
| Waves cryptocurrency | |||
| BSW.X | 0.000333 | -0.000001 | -0.38% |
| Biswap cryptocurrency | |||
| LINK.X | 10.193165 | -0.083905 | -0.82% |
| Chainlink cryptocurrency | |||
| CHZ.X | 0.010722 | -0.000159 | -1.46% |
| Chiliz cryptocurrency | |||
| GLMR.X | 0.006916 | -0.000146 | -2.07% |
| Moonbeam cryptocurrency | |||